scholarly journals PROSPECTIVE STUDY OF TRUCUT BIOPSY VS FINE NEEDLE ASPIRATION CYTOLOGY OF PROSTATE IN PATIENT WITH PROSTATE SPECIFIC ANTIGEN > 4NG/ML.

2020 ◽  
Vol 4 (11) ◽  
Author(s):  
Sarav. S. Bamania ◽  
Rajan B Somani ◽  
Soham V. Shah
Keyword(s):  
Prostate Specific Antigen ◽  
Low Cost ◽  
Prostate Gland ◽  
Specific Antigen ◽  
Clinical History ◽  
Definitive Diagnosis ◽  
Radiology Department ◽  
Biopsy Material ◽  
Trucut Biopsy ◽  
Prostate Diseases

It is often difficult for the examining finger in the rectum to decide whether the enlargement is due to benign or malignant or inflammatory conditions of the prostate such as chronic inflammation, both specific and nonspecific prostatic abscess, calculi, benign hyperplasia and carcinoma of prostate. Prostatic obstruction must be diagnosed as early as possible so that definite treatment can be instituted prevent the sequele of the obstruction. Determination of histological nature of lesion is the only positive method of establishing a definitive diagnosis. A suitable and simple technique of obtaining biopsy material and aspirational material from prostate for definitive diagnosis is essential. Aim of this study was Comparision between Trucut biopsy and FNAC in lesions of prostate gland. A prospective comparative study of Trucut biopsy vs FNAC of prostate in patient with prostate specific antigen > 4 ng/ml, was conducted among 50 patient. Patients were chosen for the study on the basis of clinical history and DRE. Patient with LUTS symptoms and enlarged Prostate on DRE were further subjected to PSA screening through blood examination at pathology lab and ultrasound for measuring prostatic volume at Radiology Department. Following consent, patients are subjected for FNAC and Trucut biopsy under local anaesthesia. Out of 50 patients, by Trucut biopsy diagnosed case of BPH are 30,Ca.Prostate are 5 and chronic prostitis are 5, while by FNAC diagnosed case of BPH are 15 , Ca.prostate are 3 and chronic prostitis are 2. In developing countries like India FNAC is more preferable due to its simplicity ,very low cost and least invasiveness and very less or no complication. Overall present studies suggest that Trucut biopsy   is superior to FNAC in diagnosis and management of prostate diseases. Keywords: FNAC,  Trucut biopsy,  Lesions of prostate gland.

scholarly journals Highly Selective Optical Sensor Eu (TTA)3 Phen Embedded in Poly Methylmethacrylate for Assessment of Total Prostate Specific Antigen Tumor Marker in Male Serum Suffering Prostate Diseases

2020 ◽  
Vol 8 ◽  
Author(s):  
Mohannad Garoub ◽  
A. H. Hefny ◽  
W. E. Omer ◽  
Mostafa M. Elsaady ◽  
Mohamed M. Abo-Aly ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Prostate Specific Antigen ◽  
Optical Sensor ◽  
Low Cost ◽  
Aqueous Media ◽  
Specific Antigen ◽  
Resonance Energy Transfer ◽  
Resonance Energy ◽  
Total Prostate Specific Antigen ◽  
Prostate Diseases

A low-cost, simple, and highly selective method was used for the assessment of total prostate specific antigen (tPSA) in the serum of prostate cancer patients. This method is based on quenching the intensity of luminescence displayed by the optical sensor Eu (TTA)3 phen/poly methylmethacrylate (PMMA) thin membrane or film upon adding different concentrations of tPSA. The luminescent optical sensor was synthesized and characterized through absorption, emission, scanning electron microscopy (SEM), and x-ray diffraction (XRD), and is tailored to present red luminescence at 614 nm upon excitation at 395 nm in water. The fabricated sensor fluorescence intensity is quenched in the presence of tPSA in aqueous media. The fluorescence resonance energy transfer (FRET) is the main mechanism by which the sensor performs. The sensor was successfully utilized to estimate tPSA in the serum of patients suffering prostate cancer in a time and cost effective way. The statistical results of the method were satisfactory with 0.0469 ng mL−1 as a detection limit and 0.99 as a correlation coefficient.

scholarly journals A Case of Advanced Submandibular Gland Cancer in Which Increased Prostate-Specific Antigen and Multiple Bone Metastases Wrongly Suggested Concurrent Prostate Cancer

2017 ◽  
Vol 10 (3) ◽  
pp. 1127-1130
Author(s):  
Yoko Fukasawa ◽  
Takeshi Honda ◽  
Maika Natsume ◽  
Terunobu Haruyama ◽  
Masashi Ishihara ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Bone Metastases ◽  
Prostate Specific Antigen ◽  
Submandibular Gland ◽  
Prostate Gland ◽  
Specific Antigen ◽  
Elevated Serum ◽  
Multiple Bone Metastases ◽  
Prostate Diseases ◽  
Submandibular Gland Cancer

A 73-year-old man, followed for prostatic hyperplasia, developed submandibular gland cancer. Initially, because of the concurrent presence of elevated serum prostate-specific antigen (PSA) and multiple bone metastases, he was clinically determined as having stage IV prostate cancer in addition to stage II submandibular gland cancer, and radical surgery for his submandibular gland cancer was performed first. However, subsequent detailed examinations of the prostate gland showed no prostate cancer, and a diagnosis of advanced submandibular gland cancer with increased PSA and multiple bone metastases was established. Serum PSA is highly specific for prostate diseases and is widely used as a tumor marker of prostate cancer. However, clinicians should be aware that, in patients with non-prostate cancer, the detection of increased PSA and multiple bone metastases does not necessarily indicate the concurrent presence of prostate cancer.

scholarly journals Differential diagnosis of uncommon prostate diseases: combining mpMRI and clinical information

2021 ◽  
Vol 12 (1) ◽  
Author(s):  
Chao Han ◽  
Lina Zhu ◽  
Xiang Liu ◽  
Shuai Ma ◽  
Yi Liu ◽  
...  
Keyword(s):  
Differential Diagnosis ◽  
Benign Prostatic Hyperplasia ◽  
Prostate Gland ◽  
Specific Antigen ◽  
Clinical Information ◽  
Clinical History ◽  
Prostatic Hyperplasia ◽  
Imaging Features ◽  
Clinically Significant ◽  
Prostate Diseases

AbstractThe differential diagnosis of abnormalities in the prostate is broad, covering common (acinar adenocarcinoma, benign prostatic hyperplasia, chronic prostatitis, hemorrhage, cysts, calcifications, atrophy and fibrosis) and less common conditions (tumors other than acinar adenocarcinoma, granulomatous prostatitis containing tuberculosis, abscesses and other conditions, and idiopathic disorders such as amyloidosis and exophytic benign prostatic hyperplasia). Recent advances in magnetic resonance imaging (MRI) of the prostate gland and imaging guidelines, such as the Prostate Imaging Reporting and Data System version 2.1 (PI-RADS v2.1), have dramatically improved the ability to distinguish common abnormalities, especially the ability to detect clinically significant prostate cancer (csPCa). Overlap can exist in the clinical history and imaging features associated with various common/uncommon prostate abnormalities, and biopsy is often required but is invasive. Prostate abnormalities can be divided into two categories: category 1, diseases for which PI-RADS scores are suitable for use, and category 2, diseases for which PI-RADS scores are unsuitable for use. Radiologists must have an intimate knowledge of other diseases, especially uncommon conditions. Past relevant history, symptoms, age, serum prostate-specific antigen (PSA) levels, MRI manifestations, and the applicability of the PI-RADS assessment should be considered when diagnosing prostate abnormalities.

scholarly journals The effect of finasteride on the prostate gland in men with elevated serum prostate-specific antigen levels

1998 ◽  
Vol 78 (3) ◽  
pp. 413-418 ◽  
Author(s):  
RJ Cote ◽  
EC Skinner ◽  
CE Salem ◽  
SJ Mertes ◽  
FZ Stanczyk ◽  
...  
Keyword(s):  
Prostate Specific Antigen ◽  
Prostate Gland ◽  
Specific Antigen ◽  
Elevated Serum ◽  
Serum Prostate Specific Antigen

scholarly journals Role of miRNALet-7and Its Major Targets in Prostate Cancer

2014 ◽  
Vol 2014 ◽  
pp. 1-14 ◽  
Author(s):  
Siegfried Wagner ◽  
Anaclet Ngezahayo ◽  
Hugo Murua Escobar ◽  
Ingo Nolte
Keyword(s):  
Prostate Cancer ◽  
Prostate Specific Antigen ◽  
Target Genes ◽  
Prostate Cancer Screening ◽  
Prostate Gland ◽  
Specific Antigen ◽  
Current Treatment ◽  
Diagnostic Potential ◽  
Major Interest ◽  
Hormone Refractory

Prostate cancer is worldwide the sixth leading cause of cancer related death in men thus early detection and successful treatment are still of major interest. The commonly performed screening of the prostate-specific antigen (PSA) is controversially discussed, as in many patients the prostate-specific antigen levels are chronically elevated in the absence of cancer. Due to the unsatisfying efficiency of available prostate cancer screening markers and the current treatment outcome of the aggressive hormone refractory prostate cancer, the evaluation of novel molecular markers and targets is considered an issue of high importance. MicroRNAs are relatively stable in body fluids orchestrating simultaneously the expression of many genes. These molecules are currently discussed to bear a greater diagnostic potential than protein-coding genes, being additionally promising therapeutic drugs and/or targets. Herein we review the potential impact of the microRNAlet-7family on prostate cancer and show how deregulation of several of its target genes could influence the cellular equilibrium in the prostate gland, promoting cancer development as they do in a variety of other human malignant neoplasias.

scholarly journals PREPARASI PEREAKSI KIT IMMUNORADIOMETRlCASSAY FREE PROSTATE SPECIFIC ANTIGEN UNTUK DETEKSI KANKER PROSTAT

2013 ◽  
Vol 15 (2) ◽  
pp. 14-24
Author(s):  
Puji Widayati ◽  
Gina Mondrida ◽  
Sri Setiyowati ◽  
Agus Ariyanto ◽  
V. Yulianti Susilo ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Prostate Specific Antigen ◽  
Prostate Gland ◽  
Specific Antigen ◽  
Prostatic Hyperplasia ◽  
Free Condition ◽  
Free Psa ◽  
Prostate Enlargement ◽  
Assay Design ◽  
Benign Prostate

Prostate Specific Antigen (PSA) is a glycoprotein with a molecular weight of approximately 34,000 daltons serine protease secreted exclusively by prostatic epithelial cells that lining acini and prostate gland. Increased of PSA levels can be caused by prostate cancer or benign prostate enlargement (benign prostatic hyperplasia, BPH). PSA in the blood was found in the free condition (free PSA) and most of the bound protein (complexed-PSA, c-PSA). Measuring levels of PSA was found in the blood can be done by several methods such as by immunoradiometricassay (IRMA) methods or ELISA methods. IRMA method is one of immunoassay techniques using radionuclides ,/' 125 oJ I as a tracer, so the sample in small 13 quantity can be detected The purpose of this study was obtained PSA reagent kit that includes 1251labeled PSA as a tracer, PSA coated tube and PSA standard that requirements of the kit, then it can be optimized assay design, that eventually PSA reagent kit can be used for early detection of prostate cancer. It has been done labeling of Mab PSA using 125 1with reaction time was 90 seconds, amount of PSA MAb was 75 ugram and the activity of Na_ 125I was 1000 flCi. Preaparation of PSA coated tube using 0.05 M Na2C03 solution, at pH: 9.6 with volume was 250 ml., standard PSA with 0.025 Mphosphate buffer at pH 7.4 containing 5% BSA and 0.1% NaN3, and resulting at 1,25% and 14,12% respectively of NSB and BIT that requirement of the kit.Keywords: Prostate cancer, PSA, IRMA,NSB, Maximum Binding

Sign in / Sign up

Export Citation Format

Share Document